Severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support
- Pre-myelotoxic therapy
- 60 mcg/kg/day IV bolus for 3 consecutive days before myelotoxic therapy, with third dose 24-48 hrs before myelotoxic therapy
- Post-myelotoxic therapy
- 60 mcg/kg/day IV bolus for 3 consecutive days post-myelotoxic therapy
- Note: Administer the first of these doses after, but on the same day of hematopoietic stem cell infusion and at least 4 days after the most recent administration of palifermin
- Safety and effectiveness in pediatric patients have not been established
